| |
Celecoxib
|
Rofecoxib
|
|---|
|
Age group
| | |
|
75+
|
5.34 (4.96–5.75)
|
3.06 (2.83–3.30)
|
|
55 to ≤74
|
3.65 (3.45–3.87)
|
2.62 (2.46–2.78)
|
|
18–54
|
Reference
|
Reference
|
|
Female sex
|
1.55 (1.47–1.62)
|
1.45 (1.38–1.52)
|
|
Income level (lower)
|
0.95 (0.88–1.02)
|
0.83 (0.77–0.89)
|
|
Prior diagnosis of gastropathy
|
1.21 (1.07–1.37)
|
1.11 (0.97–1.27)
|
|
Prior gastrointestinal procedures
|
1.21 (1.02–1.42)
|
0.97 (0.81–1.16)
|
|
Prior dispensation of gastroprotective agents
|
1.59 (1.48–1.71)
|
1.51 (1.41–1.63)
|
|
Prior referral to gastroenterologist
|
1.27 (1.11–1.45)
|
1.19 (1.03–1.37)
|
|
Prior history of NSAID use:
| | |
|
Recent, first time
|
2.25 (1.99–2.54)
|
2.02 (1.79–2.29)
|
|
Recent, chronic
|
1.68 (1.52–1.85)
|
0.75 (0.68–0.84)
|
|
>1 to 3 months
|
1.36 (1.26–1.45)
|
0.48 (0.44–0.52)
|
|
>3 to 12 months
|
0.85 (0.80–0.91)
|
0.81 (0.76–0.87)
|
|
No use in past year
|
Reference
|
Reference
|
|
Corticosteroids
|
1.11 (1.02–1.20)
|
1.20 (1.11–1.31)
|
|
Anticoagulants
|
1.61 (1.34–1.94)
|
1.48 (1.23–1.78)
|
|
Antidepressants
|
1.38 (1.28–1.48)
|
1.37 (1.27–1.48)
|
|
Benzodiazepines
|
1.18 (1.12–1.25)
|
1.15 (1.09–1.22)
|
|
Acetaminophen
|
1.39 (1.31–1.48)
|
1.37 (1.28–1.45)
|
|
Low-dose ASA
|
0.67 (0.62–0.71)
|
0.58 (0.54–0.62)
|
|
Chronic Disease Score
| | |
|
10+
|
1.26 (1.11–1.43)
|
1.20 (1.06–1.37)
|
|
5–9
|
1.28 (1.19–1.38)
|
1.23 (1.14–1.33)
|
|
1–4
|
1.25 (1.17–1.33)
|
1.26 (1.18–1.34)
|
|
0
|
Reference
|
Reference
|
|
Physician specialty
|
0.96 (0.90–1.03)
|
0.83 (0.77–0.89)
|
|
Dosage
| | |
|
High dose
|
3.36 (3.15–3.58)
|
0.76 (0.70–0.82)
|
|
Low dose
|
0.09 (0.09–0.10)
|
0.73 (0.69–0.78)
|
|
Standard dose
|
Reference
|
Reference
|
|
Time period
| | |
|
January–June
|
1.25 (1.16–1.34)
|
0.24 (0.22–0.26)
|
|
July–September
|
1.09 (1.00–1.19)
|
0.93 (0.87–1.01)
|
|
October–December
|
Reference
|
Reference
|
- ASA, acetylsalicylic acid; NSAID, nonsteroidal anti-inflammatory drug.
